2010 Press Releases Communiqués de presse

December 16, 2010 16 December, 2010

Prominent Transplant Surgeon, Dr. Steven Paraskevas, Joins Sernova Scientific Advisory Board

December 7, 2010 7 December, 2010

Sernova Provides Corporate Update And Announces Closing Of Private Placement

November 5, 2010 5 November, 2010

Sernova Completes $1,000,000 Private Placement, Grants Options

October 19, 2010 19 October, 2010

Sernova Expands Scientific Advisory Board

October 18, 2010 18 October, 2010

Sernova Corp Announces Private Placement and $570,000 First Closing

September 21, 2010 21 September, 2010

Pioneer in Islet Transplantation, Dr. James Shapiro, Joins Sernova Scientific Advisory Board

September 13, 2010 13 September, 2010

Sernova Awarded $275,000 Financial Contribution From NRC-IRAP To Support Research And Development

July 29, 2010 29 July, 2010

Ontario's Minister Goodyear Announces $45 Million Investment in Innovation and Job Creation Through NRC-IRAP at Sernova Corp.

July 12, 2010 12 July, 2010

Sernova Announces Positive Results of its Proprietary Cell Pouch System(tm) in Preclinical Diabetes Model

June 8, 2010 8 June, 2010

Sernova Completes Second Closing Of Private Placement

May 28, 2010 28 May, 2010

Sernova Presents Cell Pouch System Preclinical Results At The American Society Of Internal Artificial Organs

May 26, 2010 26 May, 2010

Appointment Of Stephen Nagler To The Sernova Business Advisory Board

April 29, 2010 29 April, 2010

Sernova Announces $1.2M Private Placement And $400,000 First Closing

April 7, 2010 7 April, 2010

Sernova To Present At Biofinance Canada Conference

March 16, 2010 16 March, 2010

Sernova Announces Interim Results from Key Preclincal Study With its Proprietary Cell Pouch System(tm)

March 2, 2010 2 March, 2010

Sernova Advances Cell Pouch System(tm) Into Non-Human Primate Studies

January 25, 2010 25 January, 2010

Sernova To Present At Biopartnering North America Conference

Press Releases from: Communiqués de presse de:

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - December 16, 2010 16 December, 2010

Prominent Transplant Surgeon, Dr. Steven Paraskevas, Joins Sernova Scientific Advisory Board


Source: Sernova Corp

FOR RELEASE

December 16, 2010, 6:00 a.m. EDT

LONDON, ONTARIO--(Marketwire -- December 16, 2010) - Sernova Corp. (TSX-V: SVA), is pleased to announce the appointment of Dr. Steven Paraskevas, MD, Ph.D., to the Corporation's Scientific Advisory Board. Dr. Paraskevas is transplant surgeon at McGill University Health Centre and Director of the Pancreas and Islet Transplant Program and of the Human Islet Isolation Laboratory at McGill.

"Dr. Paraskevas is highly respected in the islet transplant field and will be an excellent addition to Sernova's clinical development team working on the Cell Pouch(TM)," said Dr. James Shapiro, MD, Ph.D. FRCS (Eng.) FRCSC, Director of the Clinical Islet Transplantation Program at the University of Alberta and member of Sernova's scientific advisory board.

"The new islet transplantation program at McGill University headed by Dr. Paraskevas is the third such centre in Canada and provides the potential to significantly increase the number of diabetic patients that can be treated with donor islets. This advancement will not only benefit diabetic patients but will be advantageous to Sernova as it prepares for clinical development of the Cell Pouch(TM)," noted Dr. Philip Toleikis, President & CEO of Sernova Corp.

Dr Paraskevas earned a BA in Biology at Harvard University in 1988, and obtained his MD and completed General Surgery residency at McGill. During that time, he also studied mechanisms of cell death in transplanted human islets, completing a PhD in Experimental Surgery at McGill in 2003. Based on this work, he earned the Scientific Trainee Award of the Canadian Diabetes Association in 1997. After residency, he completed a two- year fellowship in abdominal solid-organ transplantation at the University of Minnesota, where he was also involved in the clinical islet transplant program under Dr Bernhard Hering. He returned to McGill in 2002 and is currently Associate Professor in Surgery and member of the multi- organ transplant program.

His current research focuses on methods to improve islet survival of human islets, paralleling the focus of Sernova's proprietary technologies. He is a Councillor-at- large of the Canadian Society of Transplantation and Chair of the Cell Transplant Committee of the American Society of Transplant Surgeons.

"Sernova is developing an eminent team of clinicians to lead the clinical evaluation of the Cell Pouch(TM) and we are thrilled to have Dr. Paraskevas as a member of that team, added Dr. David White, Chairman of Sernova's Scientific Advisory Board.

Sernova's Cell Pouch System(tm) is a scalable medical device providing a natural "organ-like" environment for therapeutic cells. Once implanted under the skin, it develops into a tissue-engineered pancreas when infused with islets. The natural environment established by the Cell Pouch System(tm) is expected to conserve cell number, and promote natural function thereby increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - December 07, 2010 7 December, 2010

Sernova Provides Corporate Update And Announces Closing Of Private Placement


*** Sernova Now Has Financial Resources to Start Clinical Trials in 2011 ***

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Source: Sernova Corp

Tuesday, December 7, 2010, 6:00 a.m. EDT

LONDON, ONTARIO--(Marketwire -- December 7, 2010) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE:SVA - News) is pleased to provide an update on activities and plans for 2011 and the closing of private placement.

Private Placement

The Company has completed a non-brokered private placement of 1,400,000 Units at a price of $0.16 per Unit raising gross proceeds of $224,000. Each Unit issued consisted of one common share of the Company (a "Share") and one-half of a share purchase warrant (a "Warrant"). Each whole Warrant entitles the holder thereof to acquire one Share at a price of $0.20 for a period of 24 months. All of the securities issued in the private placement are subject to a four month hold period that expires on April 3, 2011.

Dr. Philip Toleikis, Sernova's President & CEO, stated: "This and previous private placements have positioned Sernova with the financial resources to continue to build value through the accomplishment of several milestones during the coming year." Proceeds of the offering will be used to fund ongoing development of Sernova's proprietary Cell Pouch System(TM), including cGMP manufacturing, pre-clinical studies required by regulatory authorities to support a future Phase I/II human clinical study of insulin-dependent diabetes, and for general working capital.

Corporate Update

During 2010, we achieved a number of key milestones including:

- Refocusing our strategy around the commercialization of our Cell Pouch System(TM).

- The augmentation of our Scientific Advisory Board with the additions of Dr. James Shapiro and Dr. David Sutherland.

- Prepared for initiation of human clinical trials with the Cell Pouch System(TM) by completing a significant preclinical study demonstrating long-term glucose control in an industry-standard model of diabetes.

The Cell Pouch System(TM) is a proprietary medical device which may offer a revolutionary improvement over the current practice of injecting therapeutic cells into blood vessels. Based on previous pre-clinical research, the Cell Pouch System(tm) becomes a vascularised organ-like structure when placed in the body, providing the microcirculation thought to be essential to early function and long-term survival of therapeutic cells.

During the coming year, Sernova plans to build shareholder value by continuing to advance the Cell Pouch System(TM) into human clinical trials by:

-establishing a relationship with an ISO13485 compliant manufacturer to produce our US-FDA GMP- compliant Cell Pouch Systems(TM);

- preparing documentation to support regulatory filings required to begin human clinical trials in 2011for patients to receive donor islets;

- continuing to establish relationships with leaders in the medical community by presenting at leading transplantation conferences including: The Canadian Society of Transplantation, and World Congress of International Pancreas and Islet Transplant Association;

- presenting the validation study of the Cell Pouch System(TM) in non-human primates, assessing tissue incorporation and angiogenesis, which was conducted in collaboration with the University of Illinois at Chicago's Transplant Biology Research Laboratory; and

- presenting key results from ongoing studies of the Cell Pouch System(TM) in autograft and islet-sparing allograft porcine studies.

Another important aspect of Sernova's commercialization strategy, is establishing collaborative relationships with companies working in the cell therapy field. Based on research to date, the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases.

"Now that we have demonstrated strong efficacy in diabetes with the Cell Pouch(TM) we are hoping to establish one or more collaborations to demonstrate the expanded utility of the Cell Pouch System(TM) for other therapeutic cells during 2011," added Dr. Toleikis.

As always, we wish to thank our shareholders for their continued support of our vision to build a successful and profitable health-sciences company.

Dr. Philip Toleikis, President & CEO Sernova Corp

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - November 05, 2010 5 November, 2010

Sernova Completes $1,000,000 Private Placement, Grants Options


THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Source: Sernova Corp

Friday, November 5, 2010, 6:00 a.m. EDT

LONDON, ONTARIO - (Marketwire - November 5, 2010) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) is pleased to announce that it has completed a non-brokered private placement of 6,666,667 units (the "Units") at a price of $0.15 per Unit raising gross proceeds of $1,000,000. The private placement, which was previously announced as an offering of up to $750,000 in the Company's news release of October 18, 2010, was increased by $250,000 to accommodate oversubscriptions.

The Company completed the private placement in two closings: 2,866,667 Units were issued in the second closing on November 4, 2010 and 3,800,000 Units were issued in the first closing on October 17, 2010. Each Unit issued consisted of one common share of the Company (a "Share") and one-half of a share purchase warrant (a "Warrant"). Each whole Warrant entitles the holder thereof to acquire one Share at a price of $0.20 for a period of 24 months. In connection with the second closing, the Company paid $11,150.16 to finders and issued 21,000 finder warrants (such finder warrants having the same terms as the Warrants).

Proceeds of the offering will be used to fund ongoing development of Sernova's proprietary Cell Pouch System(TM), including cGMP manufacturing, pre-clinical studies required by regulatory authorities to support a future Phase I/II human clinical study of insulin- dependent diabetes, and for general working capital.

The terms of the private placement are subject to final acceptance by the TSX Venture Exchange. All of the securities issued in connection with the closings of the private placement are subject to resale restrictions, including a four month hold period.

Sernova also reports that it has granted incentive stock options to officers, directors and consultants to purchase up to an aggregate of 1,488,333 common shares at $0.15 per share and 250,000 common shares at $0.20 per share for a period of 5 years expiring October 28, 2015.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 19, 2010 19 October, 2010

Sernova Expands Scientific Advisory Board


Dr. David E.R. Sutherland M.D., Ph.D., Pioneer In Islet Autograft Transplantation, Joins Sernova Scientific Advisory Board

Source: Sernova Corp

LONDON, ONTARIO - (Marketwire - October 19, 2010) - Sernova Corp. (TSX-V: SVA), is pleased to announce the appointment of Dr. David Sutherland, MD, Ph.D. to the Corporation's Scientific Advisory Board.

"Dr. Sutherland joining our Scientific Advisory Board follows the Company's recent announcement of Dr. David Shapiro's appointment and represents another key component in our strategy of advancing Sernova's Cell Pouch System(TM) into Human Clinical Trials," stated Dr. Philip Toleikis, Sernova's President & CEO.

Dr. Sutherland, M.D., Ph.D. is a Professor, Transplantation Scientist and Clinician in the Division of Transplantation, Director of the Schulze Diabetes Institute and Dobbs Diabetes Research Chair within the Department of Surgery at the University of Minnesota where he oversees the largest clinical islet autotransplant program in the world.

In 1974, Dr. Surtherland pioneered islet transplantation by performing the world's first clinical islet transplant.

Dr. Sutherland is a member of the executive committee of the Collaborative Islet Transplant Registry (CITR) and has served as president of the International Transplantation Society, the American Society of Transplant Surgeons, the Cell Transplant Society, and the International Pancreas and Islet Transplant Association. He is author or co-author on over 1500 publications.

"Sernova's Cell Pouch System(TM) represents a potential opportunity to significantly optimize and simplify islet transplantation. In addition, the potential islet- sparing effect is highly attractive. I look forward to working with Sernova to advance the Cell Pouch System(TM) into human clinical trials," Said Dr. Sutherland.

Sernova's Cell Pouch System(TM) is a scalable medical device providing a natural "organ-like" environment for therapeutic cells. Once implanted under the skin, it develops into a tissue-engineered pancreas-like endocrine "organ" when infused with islets. The natural environment established by the Cell Pouch System(TM) is expected to conserve cell number, and promote natural function thereby increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.

Dr. Toleikis added, "Having both the pioneer of islet autograft transplant in Dr. Sutherland and the pioneer of the Edmonton Protocol in Dr. Shapiro associated with our company provides significant validation to our platform to deliver therapeutic cells through the Cell Pouch System(TM). We anticipate that their involvement with our Scientific Advisory Board will streamline the clinical development and commercialization of this important product."

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 18, 2010 18 October, 2010

Sernova Corp Announces Private Placement and $570,000 First Closing


THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Source: Sernova Corp

Monday, October 18, 2010, 6:00 a.m. EDT

LONDON, ONTARIO - (Marketwire - October 18, 2010) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) is pleased to announce that it is offering on a non-brokered private placement basis up to 5.0 million units (the "Units") at a price of $0.15 per Unit to raise proceeds up to $750,000. The Company completed a first closing in the amount of $570,000 on October 15, 2010.

Proceeds of the offering will be used to fund ongoing development of Sernova's proprietary Cell Pouch System(TM), including pre-clinical studies required by regulatory authorities to support a future Phase I/II human clinical study of insulin-dependent diabetes, and for general working capital.

Each of the Units consists of one common share of the Company (a "Share") and one-half share purchase warrant (a "Warrant"). Each whole Warrant entitles the holder thereof to acquire one Share at a price of $0.20 for a period of 24 months from closing. In connection with the placement, the Company may pay cash fees or issue warrants (having the same terms as the Warrants) to finders in accordance with the policies of the TSX Venture Exchange.

In the first closing, the Company issued 3,800,000 Units and 37,333 finder warrants and paid $2,800 to finders.

The terms of the private placement are subject to final acceptance by the TSX Venture Exchange. All of the securities issued in connection with a closing of the private placement will be subject to resale restrictions, including a four month hold period.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 21, 2010 21 September, 2010

Pioneer in Islet Transplantation, Dr. James Shapiro, Joins Sernova Scientific Advisory Board


LONDON, ONTARIO--(Marketwire -- September 21, 2010) - Sernova Corp. (TSX-V: SVA), is pleased to announce the appointment of Dr. James Shapiro, MD, Ph.D. FRCS (Eng.) FRCSC, to the Corporation's Scientific Advisory Board. In 2000, Dr. Shapiro led the team responsible for developing the Edmonton Protocol which was a major advancement in the treatment of insulin- dependent diabetes and now the current standard of care for Islet Transplantation.

"The experience and clinical expertise of Dr. Shapiro will be invaluable to Sernova as it continues to plan its clinical trials program." noted Dr. Philip Toleikis, President & CEO of Sernova Corp.

Dr. Shapiro, a world-renowned transplantation scientist and clinician is Director of the Clinical Islet Transplantation Program at the University of Alberta where he oversees the largest clinical islet transplant program in the world.

Dr. Shapiro's research contributions have been principally focused on improving outcomes of clinical islet transplantation. Under his leadership, an extensive network of international collaborations has been developed to study islet function, and to monitor for tolerance and autoimmune reactivity in the islet recipients receiving immunosuppression. He is Principle Investigator on a number of US National Institutes for Health (NIH) and Juvenile Diabetes Research Foundation (JDRF)- funded clinical trials, including clinical testing of co- stimulation blockade in islet transplantation and he led an international multicentre trial of the Edmonton Protocol.

"I am very impressed with the preclinical assessment of Sernova's Cell Pouch System(tm) and look forward to its clinical application," Said Dr. Shapiro.

Dr. Shapiro has been the recipient of many awards, including a Hunterian Medal from the Royal College of Surgeons of England, the Gold Medal in Surgery from the Royal College of Physicians and Surgeons of Canada, and the Governor General's Gold Medal. He is a recipient of the Meritorious Service Medal from the Governor General of Canada.

He sits on the Editorial Board of the journal Transplantation and Diabetes Therapeutics and Technology, and is an active reviewer for several journals including Nature Medicine, Transplantation, and The British Journal of Surgery.

"The Sernova team is honored by this enormous opportunity to work with such an eminent scientist and leader in the islet transplant field. We are looking forward to having Dr. Shapiro's involvement in the ongoing development of our clinical and regulatory strategy for the Cell Pouch System(tm), added Dr. David White, Chairman of Sernova's Scientific Advisory Board.

Sernova's Cell Pouch System(tm) is a scalable medical device providing a natural "organ-like" environment for therapeutic cells. Once implanted under the skin, it develops into a tissue-engineered pancreas when infused with islets. The natural environment established by the Cell Pouch System(tm) is expected to conserve cell number, and promote natural function thereby increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.

About Sernova Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 13, 2010 13 September, 2010

Sernova Awarded $275,000 Financial Contribution From NRC-IRAP To Support Research And Development


Source: Sernova Corp FOR RELEASE September 13, 2010, 6:00 a.m. EDT

LONDON, ONTARIO--(Marketwire - September 13, 2010) - Sernova Corp. (TSX-V: SVA) announced it has been awarded a second non-refundable financial contribution of up to $275,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC- IRAP).

This award will bring IRAP's total contribution to Sernova's research and development programs to $761,000 since July 2009.The new funding will be used to support study of the potential islet-sparing effect and optimal dose of islets to provide a long-term treatment for diabetic patients using Sernova's novel Cell Pouch System(TM) in a pre- clinical allograft model of diabetes.

The Cell Pouch System(TM), a proprietary medical device, is Sernova's lead product which is implanted under the skin rapidly forming into a tissue-engineered, organ-like structure that provides a natural environment for the survival and function of therapeutic cells.

Dr. Philip Toleikis said, "This IRAP contribution enables Sernova to accelerate the commercialization of the Cell Pouch System(TM) into the allograft market. Findings from this study could revolutionize the way donor islets are transplanted into patients and greatly increase the potential clinical utility of the Cell Pouch System(TM) for the treatment of diabetes worldwide."

Under the current standard of care, known as the Edmonton Protocol, donor islets are injected directly into the portal vein of the liver. This process causes an instant blood-mediated reaction (IBMIR) which destroys insulin- producing islets and leads to further side effects for patients. Sernova's previous results in an autograft setting, also supported by NRC-IRAP, suggest the cells implanted using the Cell Pouch System(TM) avoid IBMIR thereby providing efficacy with far fewer islets than required for the Edmonton Protocol.

"The potential islet-sparing of Sernova's approach would mean that islet transplantation could become a viable treatment option for millions of patients suffering from diabetes worldwide," added Toleikis.

The new study supported by the NRC-IRAP program will transplant diabetic animals with various doses of donor insulin-producing islets into Sernova's Cell Pouch System(TM) and will be completed within 12 months. Positive interim results are expected to be used to support a future clinical study in allograft patients, the largest segment of patients currently receiving donor islets.

Findings from this study could revolutionize the way islet transplantation is conducted if it is possible to treat multiple patients with a single donor pancreas.

Dr. Philip Toleikis, President and CEO of Sernova said "We are grateful to NRC-IRAP for their continued support of the commercialization of the Cell Pouch System(TM). The financial support along with technical and business- oriented advisory services, provide a distinct competitive advantage for Sernova. We look forward to commercializing our technology into multiple disease indications and major markets worldwide."

Sernova also announced the granting of incentive stock options to non-employee directors to purchase up to an aggregate of 330,000 common shares at $0.12 per share for a period of 5 years expiring September 9, 2015.

About NRC-IRAP

The National Research Council-Industrial Research Assistance Program (NRC-IRAP) is Canada's premier innovation assistance program for small and medium- sized enterprises (SMEs). It is a vital component of the NRC, a cornerstone in Canada's innovation system, regarded world-wide as one of the best programs of its kind.

Further information can be found at http://www.nrc- cnrc.gc.ca/eng/ibp/irap/about/index.html

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - July 29, 2010 29 July, 2010

Ontario's Minister Goodyear Announces $45 Million Investment in Innovation and Job Creation Through NRC-IRAP at Sernova Corp.


Source: Sernova Corp FOR IMMEDIATE RELEASE July 29, 2010

LONDON, ONTARIO--(Marketwire -- July 29, 2010) - Sernova Corp. (TSX VENTURE:SVA) is pleased that the Hon. Gary Goodyear, Minister of State for FedDev Ontario, while speaking at Sernova today, announced that as part of Canada's Economic Action Plan, FedDev Ontario will provide $45 million through the National Research Council's Industrial Research Assistance Program (NRC-IRAP) to eligible small and medium sized businesses in southern Ontario to boost their research and development capacities, increase innovation, create jobs and bring their ideas from the lab to the marketplace.

Sernova Corp. was awarded a financial contribution of $486,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC- IRAP) for 2009-2010. This non-repayable contribution, along with technical and business oriented advisory services provided by NRC-IRAP, is being used by Sernova to complete an important pre-clinical study to validate and optimize Sernova's novel Cell Pouch System(TM) device for cell transplantation into diabetic patients.

"I am very proud that our government is supporting the work of innovative businesses here in London," said Ed Holder, Member of Parliament for London West. "With our support, London companies are conducting more research and bringing new ideas into the marketplace that benefits Canadian businesses, workers and communities."

"Providing financial assistance to small and medium-sized enterprises demonstrates the National Research Council of Canada's commitment to turn knowledge into innovation," said NRC President John R. McDougall. "Sernova Corporation's entrepreneurship and dedication to developing industry-leading and internationally- recognized products is exactly the kind of drive we look for when partnering with innovative Canadian firms."

The Cell Pouch System(TM) is a proprietary device which has been developed for eventual human use and is a key component of Sernova's platform technology. The Cell Pouch System(TM) will be used initially for treatment of insulin-dependent diabetes and has the potential for use in additional cell transplantation therapies including haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases.

Dr. Philip Toleikis, Sernova's President & CEO, noted "Our Cell Pouch System(TM) is a proprietary medical device developed for human use which is implanted under the skin and rapidly forms into a tissue-engineered, organ-like structure that provides a natural environment for the survival and function of therapeutic cells. The NRC-IRAP sponsored study showed very encouraging positive long- term results in which daily insulin injections were eliminated representing a significant achievement as a possible alternative to the current practice of injecting islets directly into the portal vein of the liver. In addition, there was a significant reduction in the number of insulin- producing islets used to achieve this efficacy relative to the current standard of care for islet transplantation suggesting that the device may be islet-sparing. The financial contribution from NRC-IRAP was a key component enabling us to employ highly skilled scientists to conduct the study towards developing our products for the international market pending regulatory approval."

Based on these encouraging results, the Company is taking steps towards clinical evaluation of its Cell Pouch System(TM).

According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every eight dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - July 12, 2010 12 July, 2010

Sernova Announces Positive Results of its Proprietary Cell Pouch System(tm) in Preclinical Diabetes Model


Source: Sernova Corp

July 12, 2010, 6:00 a.m. EDT

LONDON, ONTARIO--(Marketwire -- July 12, 2010) - Sernova Corp. (TSX VENTURE:SVA) is pleased to report positive results from a long-term study evaluating the safety and efficacy of the Cell Pouch System(TM) in a pre- clinical model of diabetes.

Detailed data will be presented at the 23rd International Conference of the Transplant Society, Vancouver, British Columbia, Canada, August 15th-19th in a presentation entitled, "A novel Cell Pouch(TM), an alternative to intrahepatic islet transplantation."

Dr. Philip Toleikis, Sernova's President & CEO, noted "Our Cell Pouch System(TM) is a proprietary medical device implanted under the skin rapidly forming into a tissue- engineered, organ-like structure that provides a natural environment for the survival and function of therapeutic cells. These long-term results represent a significant achievement as a possible alternative to the current practice of injecting islets directly into the portal vein of the liver."

"Our data are profound because they suggest the potential to reduce side-effects associated with the current standard of care and achieve glucose control with significantly fewer islets than normally required," said Toleikis.

On March 16, 2010, Sernova reported initial results demonstrating that the Cell Pouch System(TM) becomes rapidly vascularised and achieved initial glucose control in subject animals.

The following summarizes important new findings reported today: Long-term insulin independence was successfully achieved with significantly fewer islets than the current standard of care, requiring only about 10% of insulin- producing islets normally used for the Edmonton Protocol. Animals in the study achieved long-term glucose normalization throughout the course of the study. Standard laboratory tests demonstrated transplanted islets produced insulin and responded similarly to non- diabetic animals to provide control of glucose. No adverse events related to the Cell Pouch System(TM) occurred during the study. About the Study

The Cell Pouch System(TM) was implanted in pigs which were then made diabetic through removing the pancreas and chemical induction. The animal's own islets (Autograft) isolated from the pancreas were transplanted into the device. Standard measures of efficacy including fasting and non-fasting glucose levels, glucose tolerance tests (IVGTT), and C-peptide were taken up to 72 days post- transplant. At the end of the study period, the device containing the islets was removed and the animals returned to a diabetic state.

Following transplantation, a substantial number of study animals maintained glucose levels within the normal range, showed glucose tolerance tests (IVGTT) similar to non-diabetic animals and were C-peptide positive, an important confirmation of insulin-producing islet function. Microscopic fluorescence analysis of the device revealed both microvessels and insulin associated with islets.

Upon removal of the Cell Pouch System(TM) containing islets, fasting glucose levels returned to the diabetic range and animals required daily insulin injections to maintain normal glucose levels. The animals return to the diabetic state was further confirmed by IVGTT and C- peptide analysis.

From a safety perspective, no adverse events occurred related to the Cell Pouch(TM) throughout the study following implantation of over 40 devices for up to 5 months. The devices were well-incorporated with collagen at all time points and yet were not visible under the skin, an important consideration for patients.

Dr. David White, Chair of Sernova's Scientific Advisory Board stated, "I am particularly enthusiastic about these results and the potential clinical relevance to patients suffering from diabetes. These new data suggest that the Cell Pouch System(TM) represent a possible clinically relevant alternative to injection of islets into the portal vein of the liver and may reduce the side effects of transplantation including the instant blood- mediated reaction (IBMR). The indication that our device achieves glucose control with a reduction in the number of islets normally required is also of profound clinical importance as it may increase the availability of life-changing islet transplantation to many diabetic patients."

Sernova believes that the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, and other chronic debilitating diseases. Based on these encouraging results, the Company is taking steps towards clinical evaluation of its Cell Pouch System(TM).

According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every eight dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 08, 2010 8 June, 2010

Sernova Completes Second Closing Of Private Placement


THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Source: Sernova Corp

Tuesday, June 8, 2010, 6:00 a.m. EDT

LONDON, ONTARIO - (Marketwire - June 8, 2010) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) is pleased to announce that is has completed a second closing of its previously announced private placement offering of units (the "Units") at a price of $0.15 per Unit. The Company raised gross proceeds of $150,720 in the second closing and has raised gross proceeds of $555,970 from the two closings.

Proceeds of the offering will be used to fund ongoing development of Sernova's proprietary Cell Pouch System(TM), including pre-clinical studies required by the FDA to support a future Phase I/II human clinical study of insulin-dependent diabetes, and for general working capital.

The Company issued 1,004,800 Units in the second closing, each Unit consisting of one common share of the Company (a "Share") and one-half share purchase warrant (a "Warrant"). Each whole Warrant entitles the holder thereof to acquire one Share at a price of $0.20 for a period of 24 months.

In connection with the second closing, the Company issued 33,880 finders' warrants ("Finders' Warrant") and approximately $5,000 was paid to finders. Each Finders' Warrant entitles the holder thereof to purchase one Share at $0.15 per Share for a period of 24 months from closing.

All of the securities issued in connection with the second closing are subject to four month hold period that expires on October 5, 2010. The offering is subject to acceptance by the TSX Venture Exchange.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 28, 2010 28 May, 2010

Sernova Presents Cell Pouch System Preclinical Results At The American Society Of Internal Artificial Organs


Source: Sernova Corp.

Friday, May 28, 2010, 6:00 a.m. EDT

LONDON, ONTARIO - (Marketwire - May 28, 2010) Sernova Corp. (TSX VENTURE:SVA) is pleased to announce that Dr. David White, chair of Sernova's Scientific Advisory Board, is presenting results from a key porcine diabetes study evaluating the safety and efficacy of the Cell Pouch System(TM).

Dr. White's podium presentation entitled "Development of a Cell Pouch to Form an Artificial Pancreas" is being presented in the "Artificial Organ Development Session" at the American Society of Artificial Internal Organs (ASAIO) 56th Annual Conference, Baltimore, MD, May 28th at 3:45 p.m.

The Cell Pouch System(TM) establishes a biological environment capable of preserving the functionality of therapeutic cells, allows for safe and long-term efficacious cell-based therapy and may offer a revolutionary improvement over the current practice of injecting therapeutic cells into blood vessels.

The Cell Pouch System(TM) is a proprietary medical device, implanted below the skin, allowing for incorporation of tissue and microvasculature to form a subcutaneous tissue-engineered pancreas, establishing an environment for the survival and functionality of insulin- producing islets and other therapeutic cells.

The study supported by a $486,000 financial contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) which involves implantation of Sernova's novel medical device into diabetic pigs to establish device parameters and optimize performance will be used as part of the regulatory documentation in support of a future Phase I/II human clinical study.

Sernova believes that the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases.

According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every eight dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 26, 2010 26 May, 2010

Appointment Of Stephen Nagler To The Sernova Business Advisory Board


Source: Sernova Corp.

Wednesday, May 26, 2010, 6:00 a.m. EDT

LONDON, ONTARIO - (Marketwire - May 26, 2010) - Sernova Corp. (TSX-V:SVA), a company focused on product development and commercialization of innovative medical technologies for cell therapies, is pleased to announce the appointment of Mr. Stephen Nagler, LLB to the Corporation's Business Advisory Board.

Mr. Nagler is Partner (Business and Finance International), Eaton Van Winkle LLC, New York. Mr. Nagler is a venture partner in Frontier Ventures, an emerging venture capital fund focused on Canadian life science companies and Chair of Tristate Ventures LLC, a leading New York City based angel investor group focused on investments in microcap companies, mostly in the healthcare sector, which he founded in 1999. Mr. Nagler is on the Advisory Board of BioContact and Chair of the International Finance program. Mr. Nagler is a graduate of the City College of New York and NYU Law School.

Dr. Philip Toleikis, President and CEO said "I am pleased to welcome Stephen to the Sernova team. He has been instrumental in assisting his numerous corporate clients to access capital through his extensive network of investment bankers, venture capitalists, and private equity groups. He has assisted his clients to raise more than $250 million in financings over the past four years and his wealth of international finance experience will be of significant benefit to the company as we progress toward our goal of becoming an internationally recognized clinical- stage product development organization."

About Sernova Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 29, 2010 29 April, 2010

Sernova Announces $1.2M Private Placement And $400,000 First Closing


THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Source: Sernova Corp

Thursday, April 29, 2010, 6:00 a.m. EDT

LONDON, ONTARIO - (Marketwire - April 29, 2010) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) is pleased to announce that it is offering on a non-brokered private placement basis up to 8.0 million units (the "Units") at a price of $0.15 per Unit to raise proceeds up to $1.2 million. The Company completed the first closing of the offering on April 28, 2010, raising $405,250 through the issuance of 2,701,666 Units.

Proceeds of the offering will be used to fund ongoing development of Sernova's proprietary Cell Pouch System(TM), including pre-clinical studies required by the FDA to support a future Phase I/II human clinical study of insulin-dependent diabetes, and for general working capital.

Each of the Units consists of one common share of the Company (a "Share") and one-half share purchase warrant (a "Warrant"). Each whole Warrant entitles the holder thereof to acquire one Share at a price of $0.20 for a period of 24 months from closing.

In connection with the first closing, the Company issued 46,923 finders' warrants ("Finders' Warrant") and approximately $7,000 was paid to finders. Each Finders' Warrant entitles the holder thereof to purchase one Share at $0.15 per Share for a period of 24 months from closing.

All of the securities issued in connection with the first closing are subject to four month hold period that expires on August 29, 2010. The offering is subject to acceptance by the TSX Venture Exchange.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 07, 2010 7 April, 2010

Sernova To Present At Biofinance Canada Conference


Source: Sernova Corp.

Wednesday, April 7, 2010, 6:00 a.m. EDT

LONDON, ONTARIO--(Marketwire - April 7, 2010) - Sernova Corp. (TSX-V:SVA), a company focused on product development and commercialization of innovative medical technologies for cell therapies, announced that its President & Chief Executive Officer will present an overview of the company's technology to a select group of biotech industry investors at the BioFinance Conference in Toronto, Ontario, Canada. Sernova's presentation is scheduled for 4:00 p.m. April 7, 2010.

The proprietary Cell Pouch System(TM), Sernova's lead technology is a novel, matchbook size medical device that is placed under the skin in a simple procedure. Once implanted, the device becomes a vascularised organ-like structure and provides the microcirculation essential to early function and long-term survival of transplanted therapeutic cells. Sernova believes the Cell Pouch System(TM) offers a valuable potential improvement to the current practise of injecting therapeutic cells directly into the bloodstream. Sernova's first application is in support of islet transplantation for treatment of insulin- dependent diabetes, where the Cell Pouch System(TM) is expected to prevent the instant blood-mediated inflammatory reaction (IBMIR) believed to rapidly destroy up to an estimated 90% of the transplanted islets and in addition eliminate serious complications such as islet- induced blood clotting and liver thrombosis. The reduction in islet loss, once verified, could lead to improved safety and efficacy of islet transplantation and the potential of treating multiple patients from a single pancreas donation.

About Sernova Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 16, 2010 16 March, 2010

Sernova Announces Interim Results from Key Preclincal Study With its Proprietary Cell Pouch System(tm)


LONDON, ONTARIO--(Marketwire -- March 16, 2010) - Sernova Corp. (TSX VENTURE:SVA) today reported interim results from a key porcine diabetes study evaluating the safety and efficacy of the Cell Pouch System(TM).

Interim results, to be presented at the American Society of Artificial Internal Organs 56th Annual Conference, Baltimore, MD, May 27th-29th in a podium presentation, confirm that the Cell Pouch System(TM) establishes a biological environment capable of preserving the functionality of therapeutic cells. The results also confirm the Cell Pouch System(TM) allows for safe and efficacious cell-based therapy and may offer a revolutionary improvement over the current practice of injecting therapeutic cells into blood vessels.

The Cell Pouch System(TM) is a proprietary medical device, implanted below the skin, allowing for incorporation of tissue and microvasculature to form an organ-like structure, establishing an environment for the survival and functionality of therapeutic cells.

The study supported by a $486,000 financial contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) involves implantation of Sernova's novel medical device into diabetic pigs to establish device parameters and optimize performance.

Dr. Philip Toleikis, Sernova's President & CEO stated, "These promising interim results are being used to finalize the device design and manufacture for the pivotal pre- clinical studies required by the FDA, in support of a future Phase I/II human clinical study."

In this study Sernova's proprietary Cell Pouch System(TM) was implanted under the skin of eight week old Yorkshire- Landrace pigs and evaluated for tissue incorporation and microvasculature development for various time periods up to eight weeks. Animals were then made diabetic using a stringent method with a combination of pancreatectomy and streptozotocin. The animal's own islets (Autograft) were isolated from the pancreas and following functional assessment, transplanted into the chambers of the Cell Pouch(TM). At intervals, various efficacy measures including fasting and non-fasting glucose levels were recorded as well as glucose tolerance tests (IVGTT) performed. After up to three months following islet transplantation, pouches were removed and efficacy measures repeated.

From an efficacy perspective, all transplant recipients showed graft function demonstrated by a reduction in blood glucose and glycemic control (IVGTT and glucose area under curve (AUC) measures). Following removal of the transplanted Cell Pouch(TM) up to the three month time point there was a significant reduction in glucose disappearance rate and glucose AUC indicating a loss of graft function. Importantly, functionality was achieved using 5% - 10% of the equivalent number of functional adult islets normally transplanted using the Edmonton Protocol procedure.

From a safety perspective, no adverse events occurred related to the Cell Pouch(TM) throughout the study following implantation of the device. The devices were well-incorporated with collagen at all time points and yet were not visible under the skin, an important consideration for patients. Quantitative blinded analysis of blood vessel growth showed significant microvasculature development in the pouches at all time points assessed. Specific differences between the device configurations will enable selection of the final device design.

"These interim results represent a significant achievement of the Cell Pouch System(TM) as a possible clinically relevant viable alternative to injection of islets into the portal vein of the liver and may reduce the side effects of such transplantation such as the instant blood- mediated reaction (IBMR)," said Dr. David White, Chair of Sernova's Scientific Advisory Board. "The potential that our device may also achieve functionality with a reduction in the number of islets normally required is also of profound clinical importance."

Sernova believes that the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases.

According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every eight dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 02, 2010 2 March, 2010

Sernova Advances Cell Pouch System(tm) Into Non-Human Primate Studies


RESEARCH TO BE CONDUCTED IN COLLABORATION WITH LEADING U.S. TRANSPLANT CENTER

LONDON, ONTARIO--(Marketwire -- March 2, 2010) - Sernova Corp. (TSX VENTURE:SVA) today announced that it has entered into a research agreement with the University of Illinois at Chicago's Transplant Biology Research Laboratory to conduct studies with its proprietary Cell Pouch System(TM) in non- human primates. Initial studies in the collaboration will evaluate the pouches sized for humans which were previously shown to form "organ-like" networks of microvessels and tissue incorporation in porcine models and represents a key validation step toward the initiation of future human clinical trials. "We are excited to be involved in the pre- clinical evaluation and advancement of Sernova's Cell Pouch System(TM)," said Dr. Amelia Bartholomew, Chief of Translational Research at UIC.

"UIC is a leading research and clinical centre for organ transplantation including islet transplantation for diabetes and it can conduct GLP-quality preclinical studies to support our future regulatory filings in preparation for clinical studies," said Dr. David White, Chair of Sernova's Scientific Advisory Board.

The Cell Pouch System(TM) is a proprietary medical device which may offer a revolutionary improvement over the current practice of injecting therapeutic cells into blood vessels. Based on previous pre-clinical research, the Cell Pouch System(TM) becomes a vascularised organ-like structure when placed in the body, providing the microcirculation thought to be essential to early function and long-term survival of therapeutic cells. Sernova believes that the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases.

"Establishing this first premier collaboration represents a key milestone in our strategy to work closely with leading transplant centers worldwide for the validation and commercialization of the Cell Pouch System(TM)," said Dr. Philip Toleikis, President & CEO of Sernova Corp.

According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

About Sernova Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - January 25, 2010 25 January, 2010

Sernova To Present At Biopartnering North America Conference


Source: Sernova Corp.

Monday, January 25, 2010, 6:00 a.m. EDT

LONDON, ONTARIO - (Marketwire - Jan. 25, 2010) - Sernova Corp. (TSX-V:SVA), a company focused on product development and commercialization of innovative medical technologies for cell therapies, announced that its President & Chief Executive Officer will present an overview of the company's technology and milestones for 2010 to a select group of biotech industry investors and potential alliance partners at the BioPartnering North America Conference in Vancouver, British Columbia. Sernova's presentation is scheduled for 9:30 a.m. January 26, 2010.

Last year, Sernova:

Appointed Dr. Philip Toleikis as President & CEO and under his leadership, Transformed and advanced its corporate strategy around its proprietary Cell Pouch System(tm) to position the company as a leader in enabling cell therapies, Successfully raised CDN$1.4 million to support this strategy through a combination of equity financings and a financial contribution from the National Research Council of Canada (NRC), Recruited key scientific staff to execute the strategic plan and several internationally recognized leaders in the business of cell therapy for Sernova's Board of Directors and Business Advisory Board, Demonstrated long-term safety and efficacy of the prototype Cell Pouch System(TM) in a small animal model of diabetes as reported at the International Islet Transplant Conference in Venice, Designed, manufactured and filed patents on the human- scaled Cell Pouch System(TM), And initiated an NRC-sponsored key proof of concept study in a large animal model of diabetes to optimize and assess the safety and efficacy of the human- scaled Cell Pouch System (TM). The proprietary Cell Pouch System(TM), Sernova's lead technology is a novel, matchbook size medical device that is placed under the skin in a simple procedure. Once implanted, the device becomes a vascularised organ-like structure and provides the microcirculation essential to early function and long-term survival of transplanted therapeutic cells. Sernova believes the Cell Pouch System(tm) offers a valuable potential improvement to the current practise of injecting therapeutic cells directly into the bloodstream. Sernova's first application is diabetes, where the Cell Pouch System(tm) is expected to prevent the instant blood-mediated inflammatory reaction (IBMIR) believed to rapidly destroy up to an estimated 90% of the transplanted islets and in addition eliminate serious complications such as islet-induced blood clotting and liver thrombosis. These improvements, once verified, could lead to the treatment of multiple patients from a single pancreas donation and improved safety and efficacy for islet transplantation.

During 2010, Sernova will seek to continue to build corporate value by advancing its core technologies toward human clinical trials and commercialization. Key objectives targeted for the upcoming year are:

To establish research collaborations with one or more leading transplant centres to conduct non-human primate studies of the Cell Pouch System(tm). Sernova is in the process of establishing relationships with groups who can conduct GLP-quality preclinical studies as requested by Health Canada and the US-FDA. Such clinical centres also currently perform the "Edmonton-protocol" transplantations and are aware of IBMIR and other complications with this procedure. To complete the current large animal study which is funded by a financial contribution of up to $486,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). The study involves the implantation of Sernova's novel medical device followed by islets into diabetic pigs to establish device parameters and optimize performance. The study commenced in August, 2009 and is expected to be completed in Q3 2010 and will generate data in part to support regulatory filings in support of a future Phase I/II human clinical study. Sernova anticipates reporting interim results during Q1 2010. To continue to seek partnerships with leaders in the cell therapy field to enhance their technology platforms using Sernova's Cell Pouch System(tm). Such partnerships would potentially enable Sernova to capture the value of its intellectual property beyond its current focus in diabetes. To continue to increase Sernova's access to industry leaders and technical expertise by expanding the Company's business and scientific advisory boards. To ensure the Company has adequate financial resources to achieve its goals through further equity financings, strategic investments and grant funding. About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(tm), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.